Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Toripalimab
The First People's Hospital of Lianyungang
Adenocarcinoma of the Stomach
1 trial -
Toripalimab
The First People's Hospital of Lianyungang
Nasopharyngeal Carcinoma
1 trial -
Toripalimab
The First People's Hospital of Lianyungang
Upper Tract Urothelial Carcinoma
1 trial -
Toripalimab
The First People's Hospital of Lianyungang
Urinary Bladder Neoplasms
1 trial -
Toripalimab
The First People's Hospital of Lianyungang
Pancreatic Carcinoma
1 trial -
Toripalimab
The First People's Hospital of Lianyungang
Small Cell Lung Cancer Limited Stage
1 trial -
Toripalimab+Nedaplatin+Albumin Paclitaxel
The First People's Hospital of Lianyungang
Locally Advanced Esophageal Squamous Cell Carcinoma
1 trial -
Total Neoadjuvant Treatment
The First People's Hospital of Lianyungang
Biliary Tract Neoplasms
1 trial -
Trilaciclib
The First People's Hospital of Lianyungang
Advanced Squamous Non-Small-Cell Lung Cancer
1 trial -
Trilaciclib
The First People's Hospital of Lianyungang
Osteosarcoma
1 trial -
Trilaciclib and Sacituzumab Tirumotecan
The First People's Hospital of Lianyungang
NSCLC (Advanced Non-small Cell Lung Cancer)
1 trial -
US-guided RFA
The First People's Hospital of Lianyungang
Liver Cancer
1 trial -
US-guided laser ablation for refractory neoplasms
The First People's Hospital of Lianyungang
Refractory Neoplasms
1 trial -
VACl
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia, Adult
1 trial -
VATS
The First People's Hospital of Lianyungang
Non-small Cell Lung Cancer
1 trial -
VEN (Venetoclax)
The First People's Hospital of Lianyungang
Adult T-cell Leukemia/Lymphoma
1 trial -
VEN (Venetoclax)
The First People's Hospital of Lianyungang
Myelodysplastic Neoplasms
1 trial -
VEN+AZA+Modified BUCY
The First People's Hospital of Lianyungang
Allogeneic Hematopoietic Stem Cell Transplantation
2 trials -
Venetoclax
The First People's Hospital of Lianyungang
Early T Acute Lymphoblastic Leukemia
1 trial -
Venetoclax
The First People's Hospital of Lianyungang
Precursor B-Cell Acute Lymphoblastic Leukemia
1 trial -
Venetoclax
The First People's Hospital of Lianyungang
Acute Leukemia of Ambiguous Lineage
1 trial -
Venetoclax, Azacitidine
The First People's Hospital of Lianyungang
T-cell Acute Lymphoblastic Leukemia
1 trial -
VenetoclaxοΌAzacitidineοΌHomoharringtonine
The First People's Hospital of Lianyungang
Secondary Acute Myeloid Leukemia
1 trial -
WJMSCs Vs. placebo
The First People's Hospital of Lianyungang
Ischemic Cardiomyopathy
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources